# US 12,599,586 B2 · Edaravone suspension for oral administration > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,599,586 B2 - Document ID: US12599586B2 - Status: Granted - Kind: B2 - Application number: 18/616,227 - Filed: 2024-03-26 - Published: 2024-07-11 - Granted: 2026-04-14 - Earliest claimed: 2018-11-02 - Assignees: K.K. Bcj-94 - Applicants: K. K. Bcj-94 - Inventors: Tetsuo Hayama; Tomohiro Takahashi; Tomoyuki Omura; Kouji Hayashi; Munetomo Matsuda; Tadashi Miyazawa - Web page: https://patentgrep.com/patent/US12599586B2 ## CPC - A61K 31/4152: having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone - A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration} - A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)} - A61K 9/10: Dispersions; Emulsions - A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)} - A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone} - A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin - A61K 47/38: Cellulose; Derivatives thereof - A61P 21/00: Drugs for disorders of the muscular or neuromuscular system - A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps - A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water. ## Claims ### Claim 1 An edaravone suspension for human oral administration, comprising: water; edaravone particles comprising edaravone and dispersed in the water; and a dispersant dispersing the edaravone particles in the water such that the dispersant maintains the edaravone particles in a solid particle state in the water, wherein the edaravone suspension is prepared by a process comprising mixing the edaravone particles having a D50 particle size in a range of 10 μm to 50 μm and a D90 particle size in a range of 50 μm to 200 μm, the water and the dispersant, and the edaravone particles have a dissolution rate of 80% of more 30 minutes after a start of a dissolution test according to Dissolution Test Method 2 of Japanese Pharmacopoeia. ### Claim 2 (depends on 1) The edaravone suspension according to claim 1, wherein the edaravone particles have a D50 particle size in a range of 10 μm to 40 μm and a D90 particle size in a range of 50 μm to 150 μm. ### Claim 3 (depends on 1) The edaravone suspension according to claim 1, wherein the edaravone particles are a pulverized product of an edaravone raw powder. ### Claim 4 (depends on 1) The edaravone suspension according to claim 1, wherein the edaravone particles have a dissolution rate of 90% or more 30 minutes after a start of a dissolution test according to Dissolution Test Method 2 of Japanese Pharmacopoeia. ### Claim 5 (depends on 4) The edaravone suspension according to claim 4, wherein the edaravone particles are a pulverized product of an edaravone raw powder. ### Claim 6 (depends on 1) The edaravone suspension according to claim 1, wherein the mixing in the process of preparing the edaravone suspension includes dissolving the dispersant in the water such that a solution comprising the water and the dispersant is prepared, and adding the edaravone particles to the solution comprising the water and the dispersant. ### Claim 7 (depends on 1) The edaravone suspension according to claim 1, wherein a blending amount of the edaravone particles is in a range of 0.2% (w/v) to 36% (w/v). ### Claim 8 (depends on 1) The edaravone suspension according to claim 1, wherein a blending amount of the dispersant is in a range of 0.001% (w/v) to 1.0% (w/v). ### Claim 9 (depends on 1) The edaravone suspension according to claim 1, wherein when edaravone in the edaravone suspension is in a range of 90 to 120 mg, edaravone in a plasma exhibits a mean Cmax in a range of 500 to 2500 ng/mL and a mean AUC0-∞ in a range of 1000 to 2500 h*ng/mL when the edaravone suspension is orally administered to a human. ### Claim 10 (depends on 1) The edaravone suspension according to claim 1, wherein when edaravone in the edaravone suspension is in a range of 90 to 120 mg, and a crossover study is performed such that the edaravone suspension is orally administered to a human and that an edaravone injection is used as a control drug product, a lower limit of a 90% confidence interval of a ratio of a Cmax geometric mean value with respect to the control drug product and a lower limit of a 90% confidence interval of a ratio of an AUC0-∞ geometric mean value with respect to the control drug product both exceed 0.8. ### Claim 11 (depends on 1) The edaravone suspension according to claim 1, wherein when edaravone in the edaravone suspension is in a range of 90 to 120 mg, and a crossover study is performed such that the edaravone suspension is orally administered to a human and that an edaravone injection is used as a control drug product, a ratio of a Cmax geometric mean value with respect to the control drug product and a ratio of an AUC0-∞ geometric mean value with respect to the control drug product are both in a range of 0.8 to 1.25. ### Claim 12 (depends on 1) The edaravone suspension according to claim 1, wherein the dispersant is a dispersant exhibiting at least one of a transmission scattering light intensity of 1% or more and a contact angle of 80 degrees or less. ### Claim 13 (depends on 1) The edaravone suspension according to claim 1, wherein the dispersant is at least one dispersant selected from the group consisting of polyvinyl alcohol, sucrose fatty acid ester, polysorbate, methylcellulose, and hypromellose. ### Claim 14 (depends on 1) The edaravone suspension according to claim 1, wherein the dispersant is at least one of polyvinyl alcohol and methylcellulose. ### Claim 15 (depends on 1) The edaravone suspension according to claim 1, wherein the dispersant is polyvinyl alcohol. ### Claim 16 (depends on 1) The edaravone suspension according to claim 1, wherein the dispersant is polyvinyl alcohol having a saponification degree in a range of 86.5 to 89.0 and a kinematic viscosity of a 4% aqueous solution in a range of 3 mm2/s to 55.7 mm2/s at 20° C. ### Claim 17 A kit for an edaravone suspension for human oral administration, comprising: edaravone particles having a D50 particle size in a range of 10 μm to 50 μm and a D90 particle size in a range of 50 μm to 200 μm; and a dispersant that dissolves in water and disperses the edaravone particles in the water such that the dispersant maintains the edaravone particles in a solid particle state in the water, wherein the edaravone particles have a dissolution rate of 80% or more 30 minutes after a start of a dissolution test according to Dissolution Test Method 2 of Japanese Pharmacopoeia. ### Claim 18 (depends on 17) The kit for an edaravone suspension according to claim 17, wherein the edaravone particles have a D50 particle size in a range of 10 μm to 40 μm and a D90 particle size in a range of 50 μm to 150 μm. ### Claim 19 (depends on 17) The kit for an edaravone suspension according to claim 17, wherein the edaravone particles are a pulverized product of an edaravone raw powder. ### Claim 20 (depends on 17) The kit for an edaravone suspension according to claim 17, wherein the edaravone particles have a dissolution rate of 90% or more 30 minutes after a start of a dissolution test according to Dissolution Test Method 2 of Japanese Pharmacopoeia.